

Press Release

Bluefront Equity investment in AquaBioTech Group

AquaBioTech Group and Bluefront Equity are pleased to jointly announce that they have entered into a letter of intent whereby Bluefront Equity will acquire a significant stake in the company through a combination of purchase of shares and new capital to accelerate the growth. The planned investment by Bluefront Equity will enable AquaBioTech Group to continue to rapidly develop its international expansion plans, including the opening of a major office in Norway and Singapore.

AquaBioTech Group consists of three main divisions. The first is an aquaculture, fisheries and marine environment consulting, advisory and training company with offices in five countries serving hundreds of international clients.

The second is the Contract Research Organisation (CRO) division, which has grown to become one of the largest licensed aquatic CRO facilities in the European Union (EU) with more than fifty research RAS units in operation. The facility is used by all of the major vetericeutical, nutraceutical and aquatic nutrition companies for the testing, development and certification of aquatic vaccines and shrimp / fish feeds.

The third is an engineering and development company focused on the turnkey supply of Recirculation Aquaculture Systems (RAS) for commercial and research purposes that are designed for a variety of fish and shrimp species, including Salmon hatcheries, nurseries and grow-out facilities.

Headquartered on the island of Malta the company was established in 1996 and has more than 100 staff recruited from over twenty-five countries and clients and projects in more than fifty-five countries. www.aquabt.com

Bluefront Equity is an Oslo based pure-play seafood investment fund created by Kjetil Haga and Simen Landmark in 2020. The core team consists of former MOWI CEO Alf Helge Aarskog, Nova Sea Chairwomen Aino Olaisen and former BioMar executive Jan Sverre Røsstad in addition to the abovementioned founding partners. www.bluefrontequity.com

Bluefront Equity promotes environmental and social characteristics as defined in Article 8 of the EU 2019/2088 Regulation on Sustainability Related Disclosures in the financial services sector (Sustainable Finance Disclosure Regulation or "SFDR").

--- END ---

A number of photographs can be provided upon request

AquaBioTech Group was established in 1996 and undertakes a variety of aquaculture, fisheries and aquatic environmental projects throughout the world, including the design, construction and operation of RAS facilities. The vast majority of the company's work is related to the marine or aquatic environment, encompassing aquaculture developments, market research / intelligence, through to project feasibility assessments, finance acquisition, project management, technology sourcing and technical support and training.

www.aquabt.com

Bluefront Equity is a pure play seafood private equity firm. **Bluefront** invests across the seafood value chain in the future of the blue economy.

- ✓ Diversified exposure to the strong megatrend of seafood in general and salmon farming in particular
- ✓ Located in Norway, the leading country within the industrialization of the seafood sector
- ✓ Dedicated and experienced founding team supported by former top executives in the seafood value chain
- ✓ Proprietary environmental, social and governance (ESG) framework integrated in the mandate

<https://www.bluefrontequity.com/>

For more information please contact:

Company:	AquaBioTech Group	www.aquabt.com
Issued by:	George D. Mantas Business Development Director	Email: gdm@aquabt.com Tel: +356 2258 4121 Mob: +356 99940835

Release Date: 24th August 2021

AquaBioTech Group

Central Complex,
Naggar Street,
Targa Gap, Mosta,
MST 1761
Malta G.C



AquaBioTech Group Logo



Bluefront Equity Logo

bluefront
equity